Phase 1 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Group A (Soft Tissue Sarcoma): People who have been diagnosed with a type of cancer called soft tissue sarcoma (STS) that has spread or cannot be surgically removed, and whose cancer has gotten worse after at least one previous treatment that included a drug from the anthracycline family of chemotherapy drugs.
- People whose cancer could be operated on but still had cancer remaining after surgery may be considered, provided the surgery took place at least 4 weeks before starting the trial treatment.
- Group B (Brain Cancer): People who have been diagnosed with a specific type of brain tumour called glioblastoma (IDH-wildtype) that has come back after receiving exactly one previous treatment (which included radiation therapy, with or without a drug called temozolomide, depending on their tumour type), and whose cancer returned at least 3 months after finishing radiation therapy.
- People who are in reasonably good general health, as measured by a standard scale called the ECOG Performance Status — specifically, those with a score of 0 or 1 (meaning able to carry out normal daily activities with little or no restriction).
- People whose blood, liver, and kidney function meet the levels required by the trial protocol.
- There may be additional requirements set out in the full trial protocol (confirm with trial site).
Who may not be able to join:
- People who have had a different type of cancer (other than soft tissue sarcoma or glioblastoma, depending on which group applies) within the past 3 years — though some exceptions may apply, such as certain skin cancers, early-stage cervical changes, benign prostate conditions, or cancers that the treating doctor considers to be fully resolved with very low chance of returning.
- Soft tissue sarcoma group only: People who have had cancer spread to the brain, to the lining surrounding the brain or spinal cord, or who have pressure on the spinal cord.
- There may be additional reasons a person would not be eligible, as set out in the full trial protocol (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Responsible, EMD Serono Research & Development Institute, Inc.
Phone: 888-275-7376
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants with Dose Limiting Toxicities (DLTs) and Adverse Events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.